SARS-CoV-2 breakthrough infection and death in COVID-19 vaccines
recipients in North of Iran in 2021
Abstract
Aim: This study aimed to assess the cases of SARS-CoV-2 breakthrough
infection and death among AZD1222, Sinopharm, Sputink V, Soberana, and
COVAXIN vaccines receivers in Mazandaran. Methods: This retrospective
cohort study was involving 320260 cases who received fully vaccinated
(two doses) with five types of COVID-19 vaccine (ChAdOx1 nCoV-19,
Sinopharm, Sputink V, Soberana, and COVAXIN) between February 2021 to
August 2021 in the Mazandaran province. The outcomes of interest were
SARS-CoV-2 breakthrough infection and death due to COVID-19 after
vaccination. Data were analyzed using R software. Results: Among 320260
COVID-19 vaccine recipients, 712 (0.22%) cases of SARS-CoV-2
breakthrough infections were identified and 94 (0.029%) hospitalized
patients died from COVID-19. The cases of SARS-CoV-2 breakthrough
infections were in Sinopharm (0.26%), ChAdOx1 nCoV-19 (0.09%), Sputnik
(0.21%) Soberana (0.01%) and Covaxin (0.38%), respectively. The cases
of death in vaccine recipients in Sinopharm, AZD1222, Sputnik, Soberana,
and Covaxin were 81, 11, 1, 1, and 0 cases, respectively. A significant
difference was observed between COVID-19 vaccines in terms of death
(P<0.05). Conclusion: Based on the findings, the most cases of
SARS-CoV-2 breakthrough infection and death were observed in Sinopharm
vaccine receivers.